AR062312A1 - Moduladores del receptor glucocorticoide ap-1y/o actividad nf- kb y uso del mismo - Google Patents
Moduladores del receptor glucocorticoide ap-1y/o actividad nf- kb y uso del mismoInfo
- Publication number
- AR062312A1 AR062312A1 ARP070103536A ARP070103536A AR062312A1 AR 062312 A1 AR062312 A1 AR 062312A1 AR P070103536 A ARP070103536 A AR P070103536A AR P070103536 A ARP070103536 A AR P070103536A AR 062312 A1 AR062312 A1 AR 062312A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- different
- formula
- substituted
- ring
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003862 glucocorticoid Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 17
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- -1 cycloalkynyl Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 abstract 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005427 anthranyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83649606P | 2006-08-09 | 2006-08-09 | |
| US11/835,438 US8034940B2 (en) | 2006-08-09 | 2007-08-08 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062312A1 true AR062312A1 (es) | 2008-10-29 |
Family
ID=39052386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103536A AR062312A1 (es) | 2006-08-09 | 2007-08-09 | Moduladores del receptor glucocorticoide ap-1y/o actividad nf- kb y uso del mismo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8034940B2 (enExample) |
| EP (1) | EP2049507A2 (enExample) |
| JP (1) | JP2010500376A (enExample) |
| KR (1) | KR20090038930A (enExample) |
| CN (1) | CN101528718B (enExample) |
| AR (1) | AR062312A1 (enExample) |
| AU (1) | AU2007286221A1 (enExample) |
| BR (1) | BRPI0716641A2 (enExample) |
| CA (1) | CA2660318A1 (enExample) |
| CL (1) | CL2007002330A1 (enExample) |
| EA (1) | EA200900291A1 (enExample) |
| IL (1) | IL196814A0 (enExample) |
| MX (1) | MX2009001220A (enExample) |
| NO (1) | NO20090564L (enExample) |
| PE (1) | PE20081314A1 (enExample) |
| TW (1) | TW200815454A (enExample) |
| WO (1) | WO2008021926A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057859A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof |
| CN101573340A (zh) | 2006-11-01 | 2009-11-04 | 百时美施贵宝公司 | 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途 |
| US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
| CN101990541A (zh) * | 2008-02-07 | 2011-03-23 | 百时美施贵宝公司 | 糖皮质激素受体、AP-1和/或NF-κB活性的稠合杂芳基调节剂及其用途 |
| AU2009233711B2 (en) * | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| US8791258B2 (en) * | 2008-06-10 | 2014-07-29 | The Regents Of The University Of California | Pro-fluorescent probes |
| WO2009158380A1 (en) * | 2008-06-24 | 2009-12-30 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof |
| JPWO2010001990A1 (ja) | 2008-07-03 | 2011-12-22 | 協和発酵キリン株式会社 | 四環系化合物 |
| WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
| US9845512B2 (en) * | 2010-01-15 | 2017-12-19 | Rigel Pharmaceuticals, Inc. | Screening assay employing Dex and GDF8 |
| WO2015027015A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imidazole-derived modulators of the glucocorticoid receptor |
| US9593113B2 (en) * | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EP3250197A1 (en) * | 2015-01-27 | 2017-12-06 | Indicator Systems International, Inc. | Fluorescein polymer conjugates |
| WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| CA3092362A1 (en) * | 2017-10-19 | 2019-04-25 | Tempest Therapeutics, Inc. | Picolinamide compounds |
| CN113862704B (zh) * | 2021-11-15 | 2023-07-21 | 南昌航空大学 | 一种9-芳基呫吨类化合物的制备方法 |
| AR127618A1 (es) | 2021-11-29 | 2024-02-14 | Bayer Ag | Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas |
| CN117105821A (zh) * | 2023-04-18 | 2023-11-24 | 重庆普佑制药有限公司 | 一种沙库比曲中间体的制备方法 |
| CN117105820A (zh) * | 2023-07-12 | 2023-11-24 | 上海阿拉丁生化科技股份有限公司 | 一种4-氟苯乙基异氰酸酯的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
| AU661337B2 (en) | 1991-09-13 | 1995-07-20 | Sankyo Company Limited | 2-(9h-xanthem-9-yl)acetamide and analogues |
| US5453421A (en) | 1992-09-11 | 1995-09-26 | E. R. Squibb & Sons, Inc. | Aryl and heterocyclic substituted propenamide derivatives |
| TW306916B (enExample) | 1994-09-13 | 1997-06-01 | Ciba Geigy Ag | |
| DE19610882A1 (de) | 1996-03-20 | 1997-09-25 | Dresden Arzneimittel | Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PL332593A1 (en) | 1996-10-04 | 1999-09-27 | Novo Nordisk As | N-substituted azaheterocyclic compounds |
| JP2000510870A (ja) | 1997-02-14 | 2000-08-22 | バイエル・コーポレーシヨン | Ｎｐｙ５受容体アンタゴニストとしてのアミド類 |
| ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
| BR0010651A (pt) | 1999-05-17 | 2002-03-19 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon |
| CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| ES2308296T3 (es) | 2003-12-19 | 2008-12-01 | Eli Lilly And Company | Modulares del receptor nuclear de hormonas esteroideas triciclicas. |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| JP4943826B2 (ja) | 2005-11-25 | 2012-05-30 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| CN101573340A (zh) | 2006-11-01 | 2009-11-04 | 百时美施贵宝公司 | 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途 |
| EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
| WO2008057859A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof |
-
2007
- 2007-08-08 US US11/835,438 patent/US8034940B2/en active Active
- 2007-08-09 CL CL200702330A patent/CL2007002330A1/es unknown
- 2007-08-09 AR ARP070103536A patent/AR062312A1/es not_active Application Discontinuation
- 2007-08-09 KR KR1020097004788A patent/KR20090038930A/ko not_active Withdrawn
- 2007-08-09 TW TW096129426A patent/TW200815454A/zh unknown
- 2007-08-09 EP EP07800057A patent/EP2049507A2/en not_active Withdrawn
- 2007-08-09 PE PE2007001067A patent/PE20081314A1/es not_active Application Discontinuation
- 2007-08-09 WO PCT/US2007/075543 patent/WO2008021926A2/en not_active Ceased
- 2007-08-09 CN CN200780037118XA patent/CN101528718B/zh not_active Expired - Fee Related
- 2007-08-09 BR BRPI0716641-9A patent/BRPI0716641A2/pt not_active Application Discontinuation
- 2007-08-09 JP JP2009523988A patent/JP2010500376A/ja not_active Withdrawn
- 2007-08-09 EA EA200900291A patent/EA200900291A1/ru unknown
- 2007-08-09 MX MX2009001220A patent/MX2009001220A/es not_active Application Discontinuation
- 2007-08-09 AU AU2007286221A patent/AU2007286221A1/en not_active Abandoned
- 2007-08-09 CA CA002660318A patent/CA2660318A1/en not_active Abandoned
-
2009
- 2009-02-01 IL IL196814A patent/IL196814A0/en unknown
- 2009-02-05 NO NO20090564A patent/NO20090564L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007286221A1 (en) | 2008-02-21 |
| PE20081314A1 (es) | 2008-10-17 |
| NO20090564L (no) | 2009-03-19 |
| TW200815454A (en) | 2008-04-01 |
| IL196814A0 (en) | 2009-11-18 |
| EP2049507A2 (en) | 2009-04-22 |
| CL2007002330A1 (es) | 2008-02-15 |
| WO2008021926A2 (en) | 2008-02-21 |
| WO2008021926A3 (en) | 2008-05-22 |
| MX2009001220A (es) | 2009-02-11 |
| CA2660318A1 (en) | 2008-02-21 |
| CN101528718A (zh) | 2009-09-09 |
| JP2010500376A (ja) | 2010-01-07 |
| CN101528718B (zh) | 2011-11-09 |
| EA200900291A1 (ru) | 2009-10-30 |
| US20090075995A1 (en) | 2009-03-19 |
| BRPI0716641A2 (pt) | 2013-10-15 |
| US8034940B2 (en) | 2011-10-11 |
| KR20090038930A (ko) | 2009-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| PE20091562A1 (es) | Derivados de naftiridinona como inhibidores de cinasa y composiciones que los comprenden | |
| AR043176A1 (es) | Derivados de bifenilo agonistas de receptores adrenergicos beta 2 y antagonistas de receptores muscarinicos | |
| AR019626A1 (es) | Antagonistas receptores y5 de neuropeptidos. | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR037748A1 (es) | Glicinamidas como inhibidores del factor xa | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR040410A1 (es) | Sulfonilaminovalerolactamas y derivados de los mismos como inhibidores del factor xa | |
| AR108156A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-cd123 | |
| AR056684A1 (es) | Derivados de acil-indol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la diabetes mellitus tipo 2. | |
| AR057872A1 (es) | Inhibidores de la proteina activadora de 5-lipoxigenasa (flap) | |
| HRP20080301T3 (en) | Biphenyl compounds useful as muscarinic receptor antagonists | |
| AR038179A1 (es) | Fenilsulfonamidas para uso terapeutico | |
| AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
| AR049664A1 (es) | Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits. | |
| AR116474A1 (es) | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV | |
| AR068521A1 (es) | Derivados heterociclicos triciclicos | |
| AR055401A1 (es) | Derivados de benzotiazolona | |
| AR068341A1 (es) | Derivados heterociclios de sulfonamidas antagonistas del receptor b1 de bradiquinina | |
| AR050274A1 (es) | Derivados triciclicos del indeno-pirrol como moduladores de la serotonina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |